Analysis of variables on diagnosis of AOSD in our series.
| Variables | AOSD Group*, n = 70 | Control Group*, n = 140 | Sensitivity, % (95% CI) | Specificity, % (95% CI) | PPV, % (95% CI) | NPV, % (95% CI) | PLR (95% CI) | NLR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Fever | ||||||||
| ≥ 39º C | 66/70 | 88/140 | 94.29 (86.01–98.42) | 37.14 (29.13–45.71) | 42.86 (34.92–51.07) | 92.86 (82.71–98.02) | 1.50 (1.30–1.73) | 0.15 (0.06–0.41) |
| ≥ 40º C | 39/70 | 31/140 | 55.71 (43.34–67.59) | 77.86 (70.07–84.43) | 55.71 (43.34–67.59) | 77.86 (70.07–84.43) | 2.52 (1.73–3.66) | 0.57 (0.43–0.75) |
| Rash | 53/70 | 29/140 | 75.71 (63.99–85.17) | 79.29 (71.62–85.67) | 64.63 (53.30–74.88) | 86.72 (79.59–92.07) | 3.65 (2.58–5.19) | 0.31 (0.20–0.47) |
| Transient erythema | 25/70 | 2/140 | 35.71 (24.61–48.07) | 98.57 (94.93–99.83) | 92.59 (75.71–99.09) | 75.41 (68.51–81.46) | 24.97 (6.10–102.54) | 0.65 (0.55–0.78) |
| Arthralgia | 56/70 | 34/140 | 80.00 (68.73–88.61) | 75.71 (67.75–82.56) | 62.22 (51.38–72.23) | 88.33 (81.20–93.47) | 3.29 (2.40–4.51) | 0.26 (0.16–0.43) |
| Myalgia | 29/70 | 29/140 | 41.43 (29.77–53.83) | 79.29 (71.62–85.67) | 50.00 (36.58–63.42) | 73.03 (65.24–79.90) | 2.00 (1.30–3.07) | 0.74 (0.60–0.92) |
| Sore throat | 51/70 | 21/140 | 72.86 (60.90–82.80) | 85.00 (77.99–90.47) | 70.83 (58.93–80.95) | 86.23 (79.34–91.50) | 4.86 (3.19–7.39) | 0.32 (0.22–0.47) |
| Leukocytes | ||||||||
| ≥ 10,000/mm3 | 55/70 | 44/140 | 78.57 (67.13–87.48) | 68.57 (60.19–76.15) | 55.56 (45.22–65.55) | 86.49 (78.69–92.23) | 2.50 (1.90–3.29) | 0.31 (0.20–0.50) |
| ≥ 15,000/mm3 | 36/70 | 17/140 | 51.43 (39.17–63.56) | 87.86 (81.27–92.76) | 67.92 (53.68–80.08) | 78.34 (71.07–84.51) | 4.24 (2.57–6.99) | 0.55 (0.43–0.71) |
| PMN | ||||||||
| ≥ 75% | 59/70 | 57/140 | 84.29 (76.62–91.89) | 59.29 (50.67–67.50) | 50.86 (41.42–60.26) | 88.30 (80.03–94.01) | 2.07 (1.66–2.59) | 0.26 (0.15–0.46) |
| ≥ 80% | 49/70 | 36/140 | 70.00 (57.87–80.38) | 74.29 (66.22–81.29) | 57.65 (46.45–68.30) | 83.20 (75.47–89.29) | 2.72 (1.98–3.75) | 0.40 (0.28–0.59) |
| ≥ 85% | 30/70 | 21/140 | 42.86 (31.09–55.25) | 85.00 (77.99 – 90.47) | 58.82 (44.17–72.42) | 74.84 (67.36–81.38) | 2.86 (1.77–4.61) | 0.67 (0.54–0.83) |
| Serum ferritin† | ||||||||
| ≥ 2N | 45/50 | 31/63 | 90.00 (79.18–96.67) | 50.79 (37.89–63.62) | 59.21 (47.33–70.35) | 86.49 (71.23–95.46) | 1.83 (1.40–2.39) | 0.20 (0.08–0.47) |
| ≥ 4N | 44/50 | 23/63 | 88.00 (75.69–95.47) | 63.49 (50.40–75.27) | 65.67 (53.06–76.85) | 86.96 (73.74–95.06) | 2.41 (1.71–3.39) | 0.19 (0.09–0.41) |
| ≥ 5N | 41/50 | 17/63 | 82.00 (68.56–91.42) | 73.02 (60.35–83.43) | 70.69 (57.27–81.91) | 83.64 (71.20–92.23) | 3.04 (1.98–4.66) | 0.25 (0.13–0.45) |
| Negative ANA | 58/68 | 84/120 | 85.29 (74.61–92.27) | 30.00 (21.98–39.04) | 40.85 (32.68–49.40) | 78.26 (63.64–89.05) | 1.22 (1.05–1.42) | 0.49 (0.26–0.92) |
| Negative RF | 54/64 | 70/101 | 84.38 (73.14–92.24) | 30.69 (21.90–40.66) | 43.55 (34.67–52.74) | 75.61 (59.70–87.64) | 1.22 (1.03–1.44) | 0.51 (0.27–0.97) |
↵* Positive cases/detection cases.
↵† Normal values 400.0 ng/ml for men, 150.0 ng/ml for women. ≥ 2N: higher than 2-fold the upper normal limit. PPV: positive predictive value; NPV: negative predictive value; PLR: likelihood ratio of positive test result; NLR: liklihood ratio of negative test result; PMN: polymorphonuclear neutrophils; ANA: anti-nuclear antibodies; RF: rheumatoid factor.